Skip to content

A Phase II Study of Pemetrexed in Elderly Patients with Previously Untreated Non-Squamous Non-Small-Cell Lung Cancer

A Phase II Study of Pemetrexed in Elderly Patients with Previously Untreated Non-Squamous Non-Small-Cell Lung Cancer - A Phase II Study of Pemetrexed in Elderly Patients with Previously Untreated Non-Squamous Non-Small-Cell Lung Cancer

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000003691
Enrollment
30
Registered
2010-06-01
Start date
2010-05-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly patients with previously untreated non-squamous non-small cell lung cancer

Interventions

Sponsors

Lung Cancer Experts Network
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1)Histologically or cytologically proven non-squamous non-small cell lung cancer 2)70 years or older 3)Previously untreated stage III/IV patients (no indication of surgery or radiotherapy) 4)ECOG PS 0-2 5)With measurable lesion 6)Adequate organ function 7)Life expectancy more than 2 months 8)Eligible in case of controlled pleural effusion 9)Eligible in case of controlled brain metastases 10)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Interstitial pneumonia or pulmonary fibrosis detectable on chest X-ray 2)Patients with superior vena cava syndrome 3)History of uncontrollable diabetes mellitus, active angina pectoris, recent myocardial infaction, and recent brain infarction 4)History of active infection 5)History of severe psychological disease 6)Hystory of active double cancer 7)History of severe drug allergy 8)History of severe heart disease 9)Patients with immunotherapy or vaccine therapy 10)Patients whose participation in the trial is judged to be inappropriate by the attending doctor

Design outcomes

Primary

MeasureTime frame
Response rate

Secondary

MeasureTime frame
Progression free survival Overall survival 1 year survival rate Safety QOL

Countries

Japan

Contacts

Public ContactNobuhiko Seki

Teikyo University Hospital Division of Medical Oncology

nseki@med.teikyo-u.ac.jp03-3964-1211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026